Structure Therapeutics Inc. (GPCR)

NASDAQ: GPCR · IEX Real-Time Price · USD
43.37
-2.43 (-5.31%)
At close: Feb 20, 2024, 4:00 PM
43.20
-0.17 (-0.39%)
After-hours: Feb 20, 2024, 6:41 PM EST
-5.31%
Market Cap 1.56B
Revenue (ttm) n/a
Net Income (ttm) -76.99M
Shares Out 35.91M
EPS (ttm) -5.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,821
Open 45.75
Previous Close 45.80
Day's Range 43.05 - 47.38
52-Week Range 20.80 - 75.02
Beta n/a
Analysts Strong Buy
Price Target 72.67 (+67.56%)
Earnings Date Mar 5, 2024

About GPCR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular di... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2023
Employees 68
Stock Exchange NASDAQ
Ticker Symbol GPCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price forecast is $72.67, which is an increase of 67.56% from the latest price.

Price Target
$72.67
(67.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.

Other symbols: VKTXTERN
4 weeks ago - CNBC

IPO watch 2024: Which new stocks will hit the market?

Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.

6 weeks ago - MarketBeat

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Other symbols: LLYNVOALTAMGNRHHBYVKTX
2 months ago - Market Watch

Structure Therapeutics reports promising results for weight-loss pill

Structure Therapeutics Inc (NASDAQ: GPCR) says its experimental weight-loss pill showed promising results in a mid-stage trial. Its shares are still down more than 40% at writing.

2 months ago - Invezz

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Biotech Structure saw shares dive after the firm disclosed disappointing data for an experimental obesity pill.

2 months ago - Barrons

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results from a similar treatment from rival Eli Lilly, sending the biotech compa...

2 months ago - Reuters

Structure Therapeutics stock plunges on new GLP-1 drug data

Structure Therapeutics Inc. American depositary receipts GPCR, +0.97% dropped 40% premarket on Monday after the company released new data from a study of GSBR-1290, its investigational diabetes and ob...

2 months ago - Market Watch

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% st...

2 months ago - GlobeNewsWire

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and tole...

3 months ago - GlobeNewsWire

Final Trades: Rivian, Pfizer, Treasury Bonds and more

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: PFERIVNTLT
5 months ago - CNBC Television

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy.

5 months ago - CNBC

Structure Therapeutics surges on promising early stage obesity drug data

Shares of Structure Therapeutics soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study.

5 months ago - Reuters

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Structure Therapeutics Inc.'s American depositary receipts GPCR, +4.96% jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss...

5 months ago - Market Watch

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors

5 months ago - GlobeNewsWire

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study

5 months ago - GlobeNewsWire

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of f...

6 months ago - GlobeNewsWire

Structure Therapeutics Appoints Ted W. Love, M.D.

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...

7 months ago - GlobeNewsWire

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

9 months ago - GlobeNewsWire

Structure Therapeutics to Present at Jefferies Healthcare Conference

SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeu...

9 months ago - GlobeNewsWire

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results  expected to be announced in latter half of fourth quarter 2023

9 months ago - GlobeNewsWire

Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 Posters include data across biomarker, translation an...

9 months ago - GlobeNewsWire

Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half 2...

10 months ago - GlobeNewsWire

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290 Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023 Completed $185.3 million upsized initial public offe...

11 months ago - GlobeNewsWire

Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therape...

1 year ago - GlobeNewsWire

Structure Therapeutics IPO prices at top of range with larger number of shares added in a sign of healthy investor interest

Structure Therapeutics Inc. GPCR, priced 10.74 million American depositary shares at $15 each to raise $161 million in its initial public offering with joint book-running managers Jefferies, SVB Secur...

1 year ago - Market Watch